Drug after drug has failed in clinical trials for fragile X syndrome. A new study provides an explanation — a decrease in the drugs’ effectiveness over time — and points to a new strategy that could circumvent this problem.
Spectrum: Autism Research News
New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.
Problems with the minute ‘factories’ that yield energy for cells — the mitochondria — may contribute to learning problems and other traits of fragile X syndrome.
Una remota ciudad colombiana es el hogar del grupo más grande de personas con síndrome de X frágil. Los científicos están aprendiendo de ellos y tratando de ayudar.
The protein missing in fragile X syndrome, FMRP, facilitates the production of hundreds of unusually large proteins, some of which are linked to autism.
Looking at the brain as a whole suggests that nudging flawed sets of neurons to collaborate better might alleviate autism traits.
Many people with fragile X syndrome show average rates of protein production, challenging a long-held assumption about the condition.
The drug mavoglurant has no effect on a brain circuit involved in social behavior in a mouse model of fragile X syndrome. That may explain its poor performance in people with the condition.